T1	Treatment 54 62	BCG plus
T2	Treatment 401 622	four vaccine groups as follows: 68 received BCG plus killed promastigotes (group A), 47 received BCG alone (group B), 47 received killed promastigotes alone (group C), and 46 formed the diluent control (placebo, group D).
T3	Treatment 623 684	Three vaccine doses were administered at 8-12 week intervals.
T4	Treatment 685 783	Vaccinees were bled immediately prior to each vaccination, and again at 3- and 12-month follow-up.
T5	Treatment 784 869	Skin tests were performed prevaccination, and again at the 3- and 12-month follow-up.
